X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9224) 9224
Book Review (1754) 1754
Publication (913) 913
Conference Proceeding (69) 69
Book Chapter (43) 43
Dissertation (14) 14
Magazine Article (11) 11
Web Resource (9) 9
Reference (2) 2
Book / eBook (1) 1
Data Set (1) 1
Government Document (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cetuximab (7513) 7513
index medicus (6644) 6644
humans (6567) 6567
oncology (4933) 4933
female (2916) 2916
male (2752) 2752
chemotherapy (2669) 2669
cancer (2524) 2524
middle aged (2372) 2372
colorectal cancer (2229) 2229
antibodies, monoclonal, humanized (2208) 2208
aged (2172) 2172
colorectal neoplasms - drug therapy (1858) 1858
antineoplastic agents - therapeutic use (1787) 1787
adult (1690) 1690
antineoplastic combined chemotherapy protocols - therapeutic use (1662) 1662
antibodies, monoclonal - therapeutic use (1617) 1617
growth-factor receptor (1593) 1593
receptor, epidermal growth factor - antagonists & inhibitors (1505) 1505
mutation (1343) 1343
egfr (1342) 1342
colorectal neoplasms - pathology (1338) 1338
treatment outcome (1324) 1324
bevacizumab (1239) 1239
care and treatment (1209) 1209
colorectal neoplasms - genetics (1164) 1164
metastasis (1160) 1160
animals (1149) 1149
therapy (1088) 1088
1st-line treatment (1014) 1014
panitumumab (1002) 1002
aged, 80 and over (1000) 1000
cell line, tumor (993) 993
epidermal growth factor (970) 970
antibodies, monoclonal - administration & dosage (950) 950
tumors (932) 932
prognosis (922) 922
fluorouracil (890) 890
metastatic colorectal-cancer (882) 882
receptor, epidermal growth factor - metabolism (875) 875
survival (858) 858
research (853) 853
radiotherapy (844) 844
kras (815) 815
oxaliplatin (814) 814
disease-free survival (809) 809
expression (806) 806
squamous-cell carcinoma (806) 806
ras proteins - genetics (791) 791
analysis (779) 779
monoclonal antibodies (775) 775
hematology, oncology and palliative medicine (732) 732
antineoplastic agents - pharmacology (723) 723
carcinoma, squamous cell - drug therapy (718) 718
mice (714) 714
neoplasm metastasis (709) 709
proto-oncogene proteins p21 (708) 708
head and neck neoplasms - drug therapy (705) 705
proto-oncogene proteins - genetics (701) 701
camptothecin - analogs & derivatives (676) 676
antineoplastic agents (666) 666
antibodies, monoclonal - adverse effects (661) 661
medicine & public health (658) 658
pharmacology & pharmacy (656) 656
squamous cell carcinoma (650) 650
drug therapy (645) 645
epidermal growth factor receptor (645) 645
head and neck cancer (636) 636
antineoplastic agents - adverse effects (630) 630
irinotecan (627) 627
antimitotic agents (623) 623
trial (620) 620
carcinoma (614) 614
cisplatin (607) 607
plus cetuximab (600) 600
leucovorin (597) 597
colorectal-cancer (591) 591
surgery (583) 583
health aspects (582) 582
neoplasm staging (576) 576
retrospective studies (576) 576
antibodies, monoclonal - pharmacology (573) 573
fluorouracil - administration & dosage (573) 573
receptor, epidermal growth factor - genetics (565) 565
cell lung-cancer (564) 564
phase-iii trial (559) 559
genetic aspects (558) 558
cancer therapies (551) 551
neoplasms (536) 536
gefitinib (526) 526
antineoplastic combined chemotherapy protocols - adverse effects (514) 514
open-label (508) 508
digestive system diseases (501) 501
phase-ii (500) 500
combination (497) 497
cetuximab plus irinotecan (493) 493
patients (491) 491
camptothecin - administration & dosage (490) 490
erlotinib (490) 490
lung neoplasms - drug therapy (486) 486
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8617) 8617
French (204) 204
German (155) 155
Japanese (136) 136
Spanish (64) 64
Chinese (50) 50
Czech (29) 29
Korean (18) 18
Hungarian (14) 14
Italian (9) 9
Turkish (7) 7
Dutch (6) 6
Polish (6) 6
Russian (6) 6
Norwegian (3) 3
Finnish (2) 2
Hebrew (2) 2
Portuguese (2) 2
Catalan (1) 1
Danish (1) 1
Persian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 12/2018, Volume 16, Issue 12, pp. 1547 - 1548
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2015, Volume 33, Issue 21, pp. 2408 - U114
Journal Article
Annals of Oncology, ISSN 0923-7534, 2015, Volume 26, Issue 8, pp. 1710 - 1714
Journal Article
10/2011
Molecular targeted agents have lower hematological toxicity. However, specific side-effects such as allergic rashes, skin reactions and high cost limit their... 
thrombosis | chemoradiotherapy | Cetuximab
Web Resource
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 1, pp. 110 - 117
Purpose To assess the rate of serious (>Grade 2, CTCAE 3.0) dermatitis in our head-and-neck cancer (HNC) patients undergoing simultaneous integrated boost... 
Radiology | Hematology, Oncology and Palliative Medicine | Cetuximab and IMRT | Cetuximab-related dermatitis | Cetuximab in irradiated head neck cancer | Cetuximab and bolus material | RADIOTHERAPY PLUS CETUXIMAB | RASH | ONCOLOGY-GROUP | PHASE-III | SECONDARY | RANDOMIZED-TRIAL | COMBINATION | RADIATION-THERAPY | CISPLATIN | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Prospective Studies | Drug Eruptions - pathology | Humans | Middle Aged | Radiodermatitis - chemically induced | Antibodies, Monoclonal - adverse effects | Male | Antineoplastic Agents - administration & dosage | Case-Control Studies | Radiotherapy, Intensity-Modulated - adverse effects | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Cetuximab | Radiodermatitis - pathology | Drug Eruptions - etiology | Radiotherapy, Intensity-Modulated - methods | Radiation Dosage | Tumor Burden | Combined Modality Therapy - adverse effects | Head and Neck Neoplasms - pathology | Head and Neck Neoplasms - radiotherapy | Antibodies, Monoclonal - administration & dosage | Aged | Combined Modality Therapy - methods | Index Medicus | HEAD | NEOPLASMS | DERMATITIS | RADIATION DOSES | SKIN DISEASES | MEDICINE | NUCLEAR MEDICINE | ORGANS | NECROSIS | DISEASES | THERAPY | DOSES | RADIOLOGY AND NUCLEAR MEDICINE | NECK | RADIOTHERAPY | SKIN | BODY | PATHOLOGICAL CHANGES | RADIOLOGY
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 09/2008, Volume 49, Issue 9, pp. 1472 - 1479
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3658 - 3666
Journal Article
05/2010
Aim: The aim of the present study was to compare the efficacy and safety of weekly versus an every 2-week administration of cetuximab in association with... 
weekly cetuximab | Cetuximab given every 2 weeks | metastatic colorectal cancer
Web Resource
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Nature, ISSN 0028-0836, 10/2015, Volume 526, Issue 7572, pp. 263 - 267
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly... 
PANITUMUMAB | THERAPY | MULTIDISCIPLINARY SCIENCES | SEQUENCE | ACQUIRED-RESISTANCE | SOMATIC MUTATION | IDENTIFICATION | GENE COPY NUMBER | ACTIVATING MUTATIONS | BREAST | INSIGHTS | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Genomics | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Molecular Targeted Therapy | Receptor, Fibroblast Growth Factor, Type 1 - genetics | MAP Kinase Kinase 1 - genetics | Colorectal Neoplasms - drug therapy | Female | Antineoplastic Agents - pharmacology | Insulin Receptor Substrate Proteins - genetics | Colorectal Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Cetuximab - pharmacology | DNA Copy Number Variations - genetics | Mutation - genetics | Genome, Human - genetics | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Exome - genetics | Animals | Receptor, Platelet-Derived Growth Factor alpha - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Gene mutations | Colorectal cancer | Drug metabolism | Genetic aspects | Identification and classification | Health aspects | Proteins | Epidermal growth factor | Genes | Clinical trials | Mutation | Kinases | Cancer therapies | Tumors | Index Medicus
Journal Article
Journal Article
The Laryngoscope, ISSN 0023-852X, 07/2017, Volume 127, Issue 7, pp. 1583 - 1588
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2017, Volume 258, pp. 196 - 207
Journal Article
Journal of Oncology Pharmacy Practice, ISSN 1078-1552, 12/2018, Volume 24, Issue 8, pp. 632 - 633
Cetuximab is a monoclonal antibody against epidermal growth factor receptor and